Kidney Today Blog

As members of the House and Senate continue to work on PDUFA reauthorization, the American Kidney Fund (AKF) is advocating that the final bill include the provisions to increase clinical trial diversity that are in the House-passed bill.

AKF Ambassador Patrick Gee discusses his experience participating in a clinical trial and why it is important for more people of color to participate in them.

AKF is expanding its health equity efforts to further increase awareness of the importance of participating in clinical trials, particularly for communities of color and other underrepresented communities.

Historically, people of color are underrepresented in clinical trials. But kidney failure disproportionately impacts Black people and Hispanics.